EXACT Therapeutics AS

As of December 31, 2024, EXACT Therapeutics AS carries a market capitalization of 237.87M, placing it among publicly traded companies globally. Its enterprise value stands at 140.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, EXACT Therapeutics AS has 63.26M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, EXACT Therapeutics AS maintains a current ratio of 3.54, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 9, 2026, EXACT Therapeutics AS's stock has declined approximately 65.00% over the past 52 weeks. The 50-day moving average sits at 0.71, while the 200-day moving average is 1.30.

As of December 31, 2024, EXACT Therapeutics AS holds 98.02M in cash and equivalents against 646,718.00 in total debt, resulting in a net debt position of -98.02M. Total book value stands at 115.55M, with working capital of 95.61M providing operational flexibility.

EXACT Therapeutics AS's most recent stock split took place on July 27, 2020 with a 1:250 split ratio.